Tarakji B, Kujan O. An immunohistochemical study of androgen receptor in carcinoma arising in pleomorphic salivary adenoma. Med Oral Patol Oral Cir Bucal. 2011 May 1;16 (3):e330-4.  

 

doi:10.4317/medoral.16.e330

http://dx.doi.org/doi:10.4317/medoral.16.e330

 

 

1. Olejniczak I, Kozłowski Z, Dabrowska K, Lukomski M. [Tumors of the parotid gland--management and results of surgical treatment]. Otolaryngol Pol. 2008;62:446-50.
doi:10.1016/S0030-6657(08)70289-0

2. Do Prado RF, Consolaro A, Taveira LA.
Expression of betacatenin in carcinoma in pleomorphic adenoma, pleomorphic adenoma and normal salivary gland: an immunohistochemical study. Med Oral Patol Oral Cir Bucal. 2006;11:E247-51.

3. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-717.
doi:10.1016/S0140-6736(05)66544-0

4. Berthelet E, Pickles T, Lee KW, Liu M, Truong PT; Prostate Cancer Outcomes Initiative. Long-term androgen deprivation therapy improves survival in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/mL. Int J Radiat Oncol Biol Phys. 2005;63:781-7.
doi:10.1016/j.ijrobp.2005.02.034
PMid:16199312

5. Ma CX, Sanchez CG, Ellis MJ. Predicting endocrine therapy responsiveness in breast cancer. Oncology (Williston Park). 2009;23:133-42.
PMid:19323294

6. Pertschuk LP, Eisenberg KB, Carter AC, Feldman JG. Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies. Correlation with biochemistry and clinical endocrine response. Cancer. 1985;55:1513-8.
doi:10.1002/1097-0142(19850401)55:7<1513::AID-CNCR2820550717>3.0.CO;2-4

7. Singh Y, Sayami P, Sayami G, Nakagawa H, Koreeda T, Hatano T, et al. Nepalese breast cancer in relation to reproductive factors: comparison between Nepalese and Japanese cases. Anticancer Res. 2002;22:319-23.
PMid:12017310

8. Dimery IW, Jones LA, Verjan RP, Raymond AK, Goepfert H, Hong WK. Estrogen receptors in normal salivary gland and salivary gland carcinoma. Arch Otolaryngol Head Neck Surg. 1987;113:1082-5.
PMid:3620130

9. Driscoll MS, Grant-Kels JM. Estrogen receptor expression in cutaneous melanoma. Arch Dermatol. 2009;145:73-5.
doi:10.1001/archdermatol.2008.539
PMid:19153347

10. Ripoll C, Ropero AB, Alonso-Magdalena P, Quesada I, Fuentes E, Nadal A. Rapid regulation of pancreatic alpha- and beta- cell signalling systems by estrogens. Infect Disord Drug Targets. 2008;8:61-4.
PMid:18473909

11. Birsak CA, Janssen PJ, van Vroonhoven CC, Peterse JL, van der Kwast TH. Sex steroid receptor expression in ‘carcinoidtumours of the breast. Breast Cancer Res Treat. 1996;40:243-9.
doi:10.1007/BF01806812
PMid:8883966

12. Mai KT, Teo I, Belanger EC, Robertson SJ, Marginean EC, Islam S. Progesterone receptor reactivity in renal oncocytoma and chromophobe renal cell carcinoma. Histopathology. 2008;52:277-82.
doi:10.1111/j.1365-2559.2007.02931.x
PMid:18081814

13. Nagao K, Matsuzaki O, Saiga H, Sugano I, Shigematsu H, Kaneko T, et al. Histopathologic studies on carcinoma in pleomorphic adenoma of the parotid gland. Cancer. 1981;48:113-21.
doi:10.1002/1097-0142(19810701)48:1<113::AID-CNCR2820480122>3.0.CO;2-F

14. Azuma M, Kasai Y, Tamatani T, Sato M. Involvement of p53 mutation in the development of human salivary gland pleomorphic adenomas. Cancer Lett. 199;65:61-71.

15. Yamamoto Y, Kishimoto Y, Virmani AK, Smith A, Vuitch F, Albores-Saavedra J, et al. Mutations associated with carcinomas arising from pleomorphic adenomas of the salivary glands. Hum Pathol. 1996;27:782-6.
doi:10.1016/S0046-8177(96)90449-9

16. Yamamoto Y, Kishimoto Y, Wistuba II, Virmani AK, Vuitch F, Gazdar AF, et al. DNA analysis at p53 locus in carcinomas arising from pleomorphic adenomas of salivary glands: comparison of molecular study and p53 immunostaining. Pathol Int. 1998;48:265-72.
doi:10.1111/j.1440-1827.1998.tb03904.x
PMid:9648154

17. Lewy-Trenda I. Estrogen and progesterone receptors in neoplastic and non-neoplastic thyroid lesions. Pol J Pathol. 2002;53:67-72.
PMid:12140869

18. Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R. Steroid hormone receptor expression in renal cell carcinoma: an immunohistochemical analysis of 182 tumors. J Urol. 2004;171:611-4.
doi:10.1097/01.ju.0000108040.14303.c2
PMid:14713771

19. Chaudhuri PK, Walker MJ, Briele HA, Beattie CW, Gupta TK. Incidence of estrogen receptor in benign nevi and human malignant melanoma. JAMA. 1980;244:791-3.
doi:10.1001/jama.244.8.791
PMid:7392187

20. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol. 2002;20:3001-15.
doi:10.1200/JCO.2002.10.018
PMid:12089231

21. Roy AK, Tyagi RK, Song CS, Lavrovsky Y, Ahn SC, Oh TS, et al. Androgen receptor: structural domains and functional dynamics after ligand-receptor interaction. Ann N Y Acad Sci. 2001;949:44-57.
doi:10.1111/j.1749-6632.2001.tb04001.x

22.
Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol. 2000;24:579-86.
doi:10.1097/00000478-200004000-00014
PMid:10757407

23. Fan CY, Melhem MF, Hosal AS, Grandis JR, Barnes EL. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg. 2001;127:1075-9.
PMid:11556855

24. Nasser SM, Faquin WC, Dayal Y. Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am J Clin Pathol. 2003;119:801-6.
doi:10.1309/RVTP1G0Q727WJUQD
PMid:12817426

25. Kapadia SB, Barnes L. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Mod Pathol. 1998;11:1033-8.
PMid:9831198

26. Moriki T, Ueta S, Takahashi T, Mitani M, Ichien M. Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. Cancer. 2001;93:344-50.
doi:10.1002/cncr.9050
PMid:11668470

27. Locati LD, Quattrone P, Bossi P, Marchianò AV, Cantù G, Licitra L. A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann Oncol. 2003;14:1327-8.
doi:10.1093/annonc/mdg331
PMid:12881399

28. Tarakji B, Nassani MZ. Immunohistochemical expression of p21 in normal tissues of salivary gland, pleomorphic adenoma and carcinoma ex pleomorphic adenoma-(undifferentiated and adenocarcinoma types).
Med Oral Patol Oral Cir Bucal. 2010;15:e697-703.
doi:10.4317/medoral.15.e697

29.
Tarakji B, Nassani MZ, Sloan P. Immunohistochemical expression of estrogens and progesterone receptors in carcinoma ex pleomorphic adenoma-undifferentiated and adenocarcinoma types. Med Oral Patol Oral Cir Bucal. 2010;15:e432-6.
doi:10.4317/medoral.15.e432